Blood Clot News and Research

RSS

A Blood Clot is a mass of blood that forms when blood platelets, proteins, and cells stick together. When a blood clot is attached to the wall of a blood vessel, it is called a thrombus. When it moves through the bloodstream and blocks the flow of blood in another part of the body, it is called an embolus.

Researchers develop new animal model for studying hemophilia A

Researchers at Yale School of Medicine have developed a new animal model for studying hemophilia A, with the goal of eventually treating people with the disorder.

3 Sep 2010

XARELTO achieves net clinical benefit in treatment of patients with DVT

Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.

2 Sep 2010

Study to determine how often chronic Lyme disease is diagnosed and treated

A study soon to be published in The Journal of Pediatrics attempts to determine how often chronic Lyme disease is actually being diagnosed and treated.

2 Sep 2010

Get With The Guidelines can improve quality of stroke care

The American Heart Association/American Stroke Association’s Get With The Guidelines®–Stroke successfully measured the quality of stroke prevention and care in a nationwide stroke registry in Taiwan and identified important areas for improvement.

31 Aug 2010

Data monitoring committee recommends early termination following impressive results of AVERROES study

The data monitoring committee of the AVERROES study, seeing overwhelming evidence of the success of apixaban in the prevention of stroke in patients with atrial fibrillation who are unsuitable for the conventional treatment of warfarin, has recommended early termination of this study. The decision came after repeated review and careful consideration of all efficacy and safety data.

31 Aug 2010

LESSON I trial provides evidence of benefits of everolimus-eluting stent over sirolimus-eluting stent

Results from the LESSON I trial presented today provide preliminary evidence for the therapeutic benefit of the newer generation everolimus-eluting stent over the previous gold standard, the early generation sirolimus-eluting stent. Moreover, LESSON I provides evidence that the formation of blood clots (stent thrombosis) - the principal shortcoming of early generation drug-eluting stents - may be diminished with the newer generation everolimus-eluting stent.

31 Aug 2010

Using clopidogrel, PPIs increases cardiac damage risk: Study

Patients with coronary artery disease undergoing stent implantation are often prescribed the antiplatelet drug, clopidogrel. This drug prevents blood clots, but is known to have a side-effect that can cause stomach bleeding. Consequently, many users are also prescribed a proton pump inhibitor (PPI). Now, however, a meta-analysis of almost 160,000 patients carried out at the Medical University of Vienna and Wilhelminenhospital, Vienna, has shown that simultaneous use of these drugs can increase the risk of cardiac damage.

31 Aug 2010

African-Americans at higher risk of developing stent thrombosis

African-American race is a distinct risk factor for developing life-threatening blood clots after receiving a drug-coated stent, according to research reported in Circulation: Journal of the American Heart Association.

31 Aug 2010

Study reveals impact of genetic make-up on response to oral antiplatelet treatment ticagrelor

A new genetic substudy of PLATO showed that the effects on a combined primary endpoint of cardiovascular death, myocardial infarction, or stroke seen in Acute Coronary Syndromes patients who received the investigational oral antiplatelet treatment, ticagrelor (BRILINTA), were maintained, whether or not they had the genetic variability that has been previously shown to affect a patient's response to clopidogrel.

30 Aug 2010

Researchers develop magnetic nanoparticles for metallic implant drug delivery

If a drug can be guided to the right place in the body, the treatment is more effective and there are fewer side-effects. Researchers at Lund University in Sweden have now developed magnetic nanoparticles that can be directed to metallic implants such as artificial knee joints, hip joints and stents in the coronary arteries.

26 Aug 2010

UT Southwestern University Hospital - St. Paul earns distinction as Primary Stroke Center

The Joint Commission has certified UT Southwestern University Hospital - St. Paul as a Primary Stroke Center, a distinction for hospitals fostering specialized stroke care for patients.

25 Aug 2010

Fluid dynamics and mechanics to simulate stent design and coating

Suncica "Sunny" Canic was good at math in school, so that's what she pursued as a career. But she always liked medicine, too. When she moved to Houston, Texas, and met some cardiologists at a party, she started talking with them about what they do-and knew she could help them.

23 Aug 2010

Simple, low-cost interventions reduce most common hospital-acquired infections

Urinary catheters are often left in place longer than needed, and new research shows that reminder systems that encourage hospital staff to remove catheters promptly can reduce the rate of catheter-associated urinary tract infections by 52 percent.

17 Aug 2010

Oral contraceptives equally effective for obese women

The first study to compare the effectiveness of the birth control pill in women with marked weight differences has found that the pill works equally well in women with obesity and thinner women. This new finding by physician-scientists at NewYork-Presbyterian Hospital/Columbia University Medical Center refutes a long-held conviction among many doctors that the pill may not reliably prevent pregnancy in women who are overweight or obese.

17 Aug 2010

Pulse Therapeutics receives fund to develop novel magnetics technique to destroy blood clots

BioGenerator, a non-profit, seed-stage economic development funding group, today announced that it has led a round of early-stage financing for Pulse Therapeutics, Inc., a St. Louis company headquartered at the Center for Emerging Technologies. Pulse Therapeutics develops innovative magnetism-based technology to safely destroy blood clots related to ischemic stroke and deep vein thrombosis (DVT). Other investors who participated in the round were Missouri Technology Corporation (MTC), Washington University's Olin School of Business Skandalaris Student Venture Fund, and Integrated Magnetics, of Culver City, California. The funds will be used for further pre-clinical development.

12 Aug 2010

PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B/2 dose-ranging clinical study with PMX-60056, a synthetic small-molecule designed to reverse heparin and low molecular weight heparin anticoagulants.

11 Aug 2010

Vena cava blood clot filters may cause potential life-threatening complications: Study

Two specific types of vena cava filters, devices used to prevent blood clots from reaching the lungs, appear to have evidence of fracturing inside the body, with some fractured fragments traveling to the heart and causing potentially life-threatening complications, according to a report posted online today that will appear in the November 8 print issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

10 Aug 2010

Scientists induce nerve tissue regeneration in patients with spinal cord injury

Researchers for the first time have induced robust regeneration of nerve tissue connections in injured adult spinal cord sites that control voluntary movement. These findings provide hope that it may be possible to design therapies for paralysis and other impairments of motor function arising from spinal cord injury.

9 Aug 2010

Blood coagulation, antimicrobial defence processes are functionally coupled: Research

The adaptive immune system can recognize and respond specifically to particular infectious agents. But the first line of defence against pathogens is the so-called innate immune system. This system reacts to invaders by initiating unspecific inflammatory responses which attract various types of specialized cells such as neutrophils to the site of the incursion.

4 Aug 2010

Researchers create artificial RNA inhibitor to block excess blood cells formation

Researchers at UT Southwestern Medical Center have uncovered a key step in the creation of new red blood cells in an animal study.They found that a tiny fragment of ribonucleic acid (RNA), a chemical cousin of DNA, prompts stem cells to mature into red blood cells. The researchers also created an artificial RNA inhibitor to block this process.

2 Aug 2010

Blood Clot News and Research

Further Reading

Researchers develop new animal model for studying hemophilia A

XARELTO achieves net clinical benefit in treatment of patients with DVT

Study to determine how often chronic Lyme disease is diagnosed and treated

Get With The Guidelines can improve quality of stroke care

Data monitoring committee recommends early termination following impressive results of AVERROES study

LESSON I trial provides evidence of benefits of everolimus-eluting stent over sirolimus-eluting stent

Using clopidogrel, PPIs increases cardiac damage risk: Study

African-Americans at higher risk of developing stent thrombosis

Study reveals impact of genetic make-up on response to oral antiplatelet treatment ticagrelor

Researchers develop magnetic nanoparticles for metallic implant drug delivery

UT Southwestern University Hospital - St. Paul earns distinction as Primary Stroke Center

Fluid dynamics and mechanics to simulate stent design and coating

Simple, low-cost interventions reduce most common hospital-acquired infections

Oral contraceptives equally effective for obese women

Pulse Therapeutics receives fund to develop novel magnetics technique to destroy blood clots

PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints

Vena cava blood clot filters may cause potential life-threatening complications: Study

Scientists induce nerve tissue regeneration in patients with spinal cord injury

Blood coagulation, antimicrobial defence processes are functionally coupled: Research

Researchers create artificial RNA inhibitor to block excess blood cells formation

Industry Focus eBook - Cell biology (5th edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News